文献速递老年慢病共病管理衰弱、肌少症与跌倒

阿司匹林与老年人健康寿命:ASPREE-XT观察性研究主要结局

Aspirin and healthy lifespan in older people: main outcome of the ASPREE-XT observational study.
PubMed 文献 · Lancet Healthy Longev · 2025-09-30

BACKGROUND: In the Aspirin in Reducing Events in the Elderly (ASPREE) clinical trial, low-dose aspirin was not associated with survival free of dementia and persistent physical disability (a measure of a healthy lifespan); however, there was a small increased risk of death.…

要点

  • 对健康老年人不应以促进健康寿命为目的使用低剂量阿司匹林。

核心结论

  • 低剂量阿司匹林对初始健康的社区居住老年人健康寿命无促进作用。

关键数值与推荐

  • 主要终点为痴呆、持续身体残疾或死亡的复合结局,由盲法专家小组裁定。
  • 分析采用Cox比例风险模型,意向性治疗原则。

临床怎么用

  • 对于初始健康的社区居住老年人,不应以促进健康寿命为目的常规使用低剂量阿司匹林。

局限性

  • ASPREE-XT为观察性随访,非随机对照,可能存在残余混杂。
  • 研究人群主要为70岁及以上、初始健康的社区居住老年人,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the Aspirin in Reducing Events in the Elderly (ASPREE) clinical trial, low-dose aspirin was not associated with survival free of dementia and persistent physical disability (a measure of a healthy lifespan); however, there was a small increased risk of death. Given the long pre-clinical phase of many ageing conditions, we aimed to examine the legacy effect (post-trial) and the longer-term effect of aspirin versus placebo through extended follow-up in the ASPREE-XT observational study. METHODS: Between March 10, 2010, and Dec 24, 2014, 19 114 community-dwelling people in Australia and the USA, aged predominantly 70 years and older, were randomly assigned to low-dose aspirin or placebo for a median of 4·7 years as part of the ASPREE trial. Post-trial observational follow-up continued for a median of 4·3 years (IQR 4·1-4·6). All components of the primary endpoint (ie, incident dementia, persistent physical disability, and death) were adjudicated by masked expert panels. Analyses used Cox proportional hazards models with intention-to-treat. FINDINGS: 15 633 participants (8836 [56·5%] were women, 6797 [43·5%] were men; 981 [6·3%] were not White) were eligible for and agreed to observational follow-up. There was no effect of randomisation to aspirin (34·37 events per 1000 person-years) versus placebo (33·68 per 1000 person-years) on the primary endpoint (hazard ratio [HR] 1·02; 95% CI 0·94-1·11; p=0·63) in the ASPREE-XT period. Similarly, over the period of both ASPREE and ASPREE-XT, no long-term effect of aspirin versus placebo was observed on the composite outcome of death, dementia, or persistent physical disability over almost a decade of follow-up (HR 1·01; 95% CI 0·95-1·08; p=0·65), including no long-term effect on deaths (1·06; 0·99-1·14; p=0·10). No effect of aspirin on incident major haemorrhagic events as compared with placebo was found in ASPREE-XT; however, aspirin was associated with an increased hazard for incident major haemorrhagic events across both ASPREE and ASPREE-XT (1·24; 1·10-1·39). INTERPRETATION: Low-dose aspirin does not appear to be effective in promoting a healthy lifespan in initially healthy, community-dwelling older people. FUNDING: National Institute on Aging and the National Cancer Institute (USA).

来源:Lancet Healthy Longev,查看原文。版权归原作者所有。

引用

  1. Shah RC, Ryan J, Webb KL, et al. Aspirin and healthy lifespan in older people: main outcome of the ASPREE-XT observational study. Lancet Healthy Longev. 2025. PMID: 41043446. doi:10.1016/j.lanhl.2025.100764

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。